Xi D Chen

US Patent:

6429312, Aug 6, 2002

Filed:

Mar 19, 2001

Appl. No.:

09/812199

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40914

US Classification:

544295, 544363, 544364, 544375, 544376, 544333, 5462811, 546146, 546175, 546194, 546202, 546256, 549 43, 549 48

Abstract:

Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R , R , R , R are the same or different and represent hydrogen, C -C alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C -C alkoxy, âO CRâ, âNHCORâ, âCORâ, âSO Râ, where Râ is C -C alkyl and wherein m is 0, 1 or 2; or R , R , R , R independently represent âCONRâRâ, or âNRâRâ where Râ and Râ independently represent hydrogen or C -C alkyl; R is hydrogen or C -C alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimers disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

US Patent:

8134864, Mar 13, 2012

Filed:

Aug 13, 2009

Appl. No.:

12/541111

Inventors:

Randall H. Victora - New Brighton MN, US
Xi Chen - Minneapolis MN, US

Assignee:

Regents of the University of Minnesota - St. Paul MN

International Classification:

G11C 11/00

US Classification:

365158, 365171, 365173

Abstract:

In general, the invention is directed to techniques for reducing the amount of switching current that is utilized within a magnetic storage (e. g. , MRAM) device. An example apparatus includes a fixed magnetic layer that provides a fixed direction of magnetization, an exchange-coupled magnetic multi-layer structure, and a non-magnetic layer placed between the fixed magnetic layer and the exchange-coupled magnetic multi-layer structure. The exchange-coupled magnetic multi-layer structure includes a recording layer configured to record information and an assisting layer having a lower anisotropy than the recording layer. The exchange coupling between the recording and assisting layers is operable to switch a magnetization direction of the recording layer. In some cases, the exchange-coupled magnetic multi-layer structure may further include a spacer separating the recording and assisting layers and configured to weaken an exchange coupling between the recording and assisting layers.

US Patent:

20060100225, May 11, 2006

Filed:

Mar 23, 2005

Appl. No.:

11/088276

Inventors:

Xi Chen - Killingworth CT, US
Andrew Thurkauf - Ridgefield CT, US
Shirley Louise-May - Guilford CT, US

International Classification:

A61K 31/513
A61K 31/505
C07D 239/32

US Classification:

514269000, 514275000, 544320000, 544330000

Abstract:

Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A, R, R, R, Rand Rare defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

US Patent:

57636095, Jun 9, 1998

Filed:

Mar 21, 1996

Appl. No.:

8/619429

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40914
C07D40912

US Classification:

544363

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 5 is hydrogen or C. sub. 1 -C. sub. 6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

US Patent:

57032351, Dec 30, 1997

Filed:

Mar 21, 1996

Appl. No.:

8/619351

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40110
C07D29515
C07D21114
C07D21170

US Classification:

544363

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 10 is hydrogen or C. sub. 1 -C. sub.

US Patent:

60342528, Mar 7, 2000

Filed:

Jun 8, 1999

Appl. No.:

9/328170

Inventors:

Xi Chen - Killingworth CT
Jan W. F. Wasley - Guilford CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D49504

US Classification:

5483595

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable salts thereof wherein wherein: R. sub. 1, R. sub. 2, and and R. sub. 4 independenlty represent hydrogen, halogen, alkyl, cyano, alkoxycarbonyl, trifluoromethoxy, SO. sub. 2 NH. sub. 2 or trifluoromethyl; R. sub. 3 represents hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, amino, mono- or di(C. sub. 1 -C. sub. 6)alkylamino, cyano, alkoxycarbonyl, trifluoromethoxy, SO. sub. 2 NH. sub. 2 or trifluoromethyl; or R. sub. 3 represents optionally substituted phenyl; X represents (CH. sub. 2). sub. n where n is an integer; and m is 0 or an integer, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

US Patent:

58832572, Mar 16, 1999

Filed:

Dec 19, 1997

Appl. No.:

8/994588

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40112
C07D21170
C07D21114

US Classification:

546203

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 5, R. sub. 6, R. sub. 7, R. sub. 8 and R. sub. 9 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 10 is hydrogen or C. sub. 1 -C. sub.

US Patent:

60404590, Mar 21, 2000

Filed:

Aug 5, 1999

Appl. No.:

9/368542

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D33376

US Classification:

549 43

Abstract:

Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 are the same or different and represent hydrogen, C. sub. 1 -C. sub. 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C. sub. 1 -C. sub. 6 alkoxy, --O. sub. 2 CR', --NHCOR', --COR', --SO. sub. m R', where R' is C. sub. 1 -C. sub. 6 alkyl and wherein m is 0, 1 or 2; or R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C. sub. 1 -C. sub. 6 alkyl; R. sub. 5 is hydrogen or C. sub. 1 -C. sub. 6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.